Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Sales and Divestitures (2018 - 2025)

Sutro Biopharma (STRO) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $252107.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 85.13% to $252107.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $252107.0 through Dec 2025, down 85.13% year-over-year, with the annual reading at $252107.0 for FY2025, 85.13% down from the prior year.
  • Gains from Sales and Divestitures hit $252107.0 in Q4 2025 for Sutro Biopharma, down from $2.3 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.3 million in Q3 2025 to a low of $147349.0 in Q1 2021.
  • Historically, Gains from Sales and Divestitures has averaged $936361.2 across 5 years, with a median of $849019.0 in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 265.86% in 2021 and later tumbled 85.13% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $238724.0 in 2021, then skyrocketed by 159.99% to $620647.0 in 2022, then skyrocketed by 86.2% to $1.2 million in 2023, then skyrocketed by 46.68% to $1.7 million in 2024, then crashed by 85.13% to $252107.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for STRO at $252107.0 in Q4 2025, $2.3 million in Q3 2025, and $2.0 million in Q2 2025.